• Our Company
    • Our Company
      • Therapeutics
      • Precision Medicine
      • MedTech
      • Telix Manufacturing Solutions
    • Our Technology
    • Partnering with Telix
    • Board & Management
    • Sustainability
  • Our Portfolio and Pipeline
    • Disease Areas
      • Urologic Oncology
      • Neurologic Oncology
      • Other Tumors
    • Our Pipeline
    • Our Portfolio
    • Research & Development
  • Clinical Trials
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a Job
  • Our Company
    • Our Company
      • Therapeutics
      • Precision Medicine
      • MedTech
      • Telix Manufacturing Solutions
    • Our Technology
    • Partnering with Telix
    • Board & Management
    • Sustainability
  • Our Portfolio and Pipeline
    • Disease Areas
      • Urologic Oncology
      • Neurologic Oncology
      • Other Tumors
    • Our Pipeline
    • Our Portfolio
    • Research & Development
  • Clinical Trials
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a Job
Home News & Views

News & Views

FILTER:
All ASX BD&AM Clinical Events News Scientific Publication Uncategorized

Telix Pharmaceuticals and Global Medical Solutions Complete Strategic Manufacturing Agreement

Telix announces it has completed a strategic manufacturing agreement with Global Medical Solutions to manufacture and supply finished unit doses of MTR products for clinical development programs.
Read more

Japanese Renal Cancer Imaging Trial Meets Study Objectives

Telix announces the Company’s ZIRDAC-JP study of its renal cancer imaging product demonstrates safety and tolerability in Japanese patients.
Read more

Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent

Telix announces the launch of the international NOBLE Registry of Telix’s ‘rest of world’ prostate cancer imaging agent and the dosing of the first patient
Read more

Australian TGA Accepts Telix’s Prostate Cancer Imaging Product Submission and Commences Priority Evaluation Process

Telix announces the Australian Therapeutic Goods Administration has accepted its prostate cancer imaging product submission and commenced the priority evaluation process
Read more

Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021

Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12 May 2021
Read more

Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®

Telix announces it has completed an agreement with Grand River Aseptic Manufacturing to perform GMP manufacturing of Telix’s prostate cancer imaging product.
Read more

Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

Telix is delighted to announce the appointment of Darren Patti as Chief Operating Officer, Telix Pharmaceuticals US (Inc). Darren brings with him over 15 years’ experience in radiopharmacy network management and operations, including new radiopharmaceuticals implementation and compliance.
Read more

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Telix announces it has extended its non-exclusive global clinical and commercial supply agreements with Garching-based ITM AG
Read more

Telix Appoints Sébastien Linard as General Manager, Telix European Manufacturing Facility

Telix is delighted to announce the appointment of Sébastien Linard to the position of General Manager of Telix’s European Manufacturing in Seneffe, Belgium.
Read more

AUDIO LINK NOT INCLUDED – Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report

Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual Report.
Read more

Posts pagination

Previous page 1 … 40 41 42 … 53 Next page
  • Our Company
  • Our Portfolio
  • Investor Center
  • News & Views
  • Careers
  • Contact Us
  • Telix Hotline
  • Legal Notices

Subscribe to our newsletter to stay in the loop

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.​
The Telix Pharmaceuticals, the Illuccix and Gozellix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.​
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.​

  • Privacy Policy
  • Terms of Use
  • Cookies Policy
  • Consumer Health Privacy Notice
  • Privacy Settings

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”